Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:51:32.515Z.
Consensus retrieved: 2026-10-06T11:22:16.278Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:51:32.515Z.
Quote observation: 2026-10-06T16:50:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f516b86ce6f8a32b007838909cf85d374f635633f340bc308fa792387434ce1
Forward PE Ratio (N/A) = Dated Quote Price ($2.35) / Consensus Forward EPS ($-1.07)
FORWARD PE RATIO
N/A
Fate Therapeutics, Inc.
Market Cap
$273.33M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $273.33M | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $272.44M | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.73M | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $276.60M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.81M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.35M | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $265.41M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.30M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.26M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.35, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.07 | $-1.15 – $-0.85 | 8 | n/m |
| 2027-12-31 | $-1.05 | $-1.35 – $-0.58 | 7 | n/m |
| 2028-12-31 | $-1.10 | $-1.60 – $-0.80 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
